# Thomas Holst‐Hansen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thomas-holst-hansen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 502 |
| Field | Diabetes Treatment and Management |
| h-index | 6 |
| i10-index | 5 |
| OpenAlex ID | https://openalex.org/A5049206475 |
| ORCID iD | 0000-0002-5314-7802 |
| Works | 22 |

## Researcher papers

- [Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/oral-semaglutide-50-mg-taken-once-per-day-in-adults-with-overweight-or-obesity/)
- [Spatiotemporal NF-κB dynamics encodes the position, amplitude, and duration of local immune inputs](https://scholariq.org/papers/spatiotemporal-nf-b-dynamics-encodes-the-position-amplitude-and-duration-of-2/)
- [Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity](https://scholariq.org/papers/effect-of-semaglutide-2-4-mg-once-weekly-on-10-year-type-2-diabetes-risk-in/)
- [The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis](https://scholariq.org/papers/the-association-between-body-mass-index-and-health-related-quality-of-life-in/)
- [Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial](https://scholariq.org/papers/efficacy-and-safety-of-monlunabant-in-adults-with-obesity-and-metabolic-syndrome/)
- [2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity](https://scholariq.org/papers/2-lb-semaglutide-2-4-mg-reduces-the-10-year-t2d-risk-in-people-with-overweight/)
- [The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials](https://scholariq.org/papers/the-improved-health-utility-of-once-weekly-subcutaneous-semaglutide-2-4-mg/)
- [Treatment effect of semaglutide 2.4 mg on health‐related quality of life from <scp>STEP</scp> 1 <scp>SF‐6D</scp> derived from <scp>SF</scp> ‐36 with Australian weights](https://scholariq.org/papers/treatment-effect-of-semaglutide-2-4-mg-on-health-related-quality-of-life-from/)
- [Spatiotemporal NF-κB dynamics encodes the position, amplitude and duration of local immune inputs](https://scholariq.org/papers/spatiotemporal-nf-b-dynamics-encodes-the-position-amplitude-and-duration-of/)
- [The Correlation Between Body Mass Index and Health-Related Quality of Life: Data from Two Weight Loss Intervention Studies](https://scholariq.org/papers/the-correlation-between-body-mass-index-and-health-related-quality-of-life-data/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Pharmacology and Obesity Treatment](https://scholariq.org/topics/pharmacology-and-obesity-treatment/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.